Optomed Plc, stock exchange release, 28 February 2020 at 9.00 EET
Optomed’s Financial Statements Bulletin January–December 2019
October–December 2019 highlights
· Revenue decreased, as expected by 7.7 percent to EUR 4,329 (4,688) thousand
· Strong sales within the Devices segment’s OEM channel and Software segment
were offset by a large Chinese customer postponing orders to 2020, affecting
both the fourth quarter and full year revenue
· Adjusted EBITDA amounted to EUR -211 (1,102) thousand corresponding to -4.9
(23.5) percent of revenue
· Successful initial public offering (IPO) concluded in December 2019, which
strengthened the company’s cash position, balance sheet and equity ratio with
gross proceeds of 20 MEUR, before the payment of IPO related expenses
January–December 2019 highlights
· Revenue increased by 3.6 percent to EUR 14,977 (14,463) thousand on a
proforma basis, a low single digit growth as expected
· Adjusted EBITDA amounted to EUR -196 (1,661) thousand and -1.3 (11.5)
percent of revenue
Key figures
EUR, thousand Q4/201 Q4/201 Change, 2019 Proforma Change, %
9 8 % 2018
Revenue 4,329 4,688 -7.7% 14,977 14,463 3.6%
Gross profit * 2,745 3,530 -22.2% 9,944 10,398 -7.8%
Gross margin *, % 63.4% 75.3% 66.4% 71.9%
EBITDA 550 968 -43.2% -335 1,188 -128.2%
EBITDA margin *, % 12.7% 20.7% -2.2% 8.2%
Adjusted EBITDA * -211 1,102 -119.1% -196 1,661 -111.8%
Adjusted EBITDA margin -4.9% 23.5% -1.3% 11.5%
*, %
Operating result -33 453 -107.4% -2,596 -664 -291.0%
(EBIT)
Operating margin -0.8% 9.7% -17.3% -4.6%
(EBIT) *, %
Adjusted operating -794 588 -234.9% -2,457 -338 -625.8%
result (EBIT) *
Adjusted operating -18.3% 12.6% -16.4% -2.3%
margin (EBIT margin)
*, %
Net profit/ loss -58 449 -116.6% -2,875 -1,327 -116.7%
Earnings per share -0.01 0.06 -111.4% -0.32 -0.17 -90.4%
Cash flow from 2,000 1,375 52.9% 161 -76 311.8%
operating activities
Net debt -8,938 8,207 -208.9% -8,938 8,207 -208.9%
Net debt/ Adjusted 45.7 4.9 45.7 4.9
EBITDA (LTM) *
Equity ratio * 57.2% 24.0% 57.2% 24.0%
R&D expenses personnel 210 152 37.9% 1,245 1,369 -9.0%
R&D expenses other 378 100 276.9% 529 188 180.6%
costs
Total R&D expenses 588 254 131.9% 1,774 1,557 14.0%
*) Alternative performance measures, see section Alternative Performance
Measures for definitions and calculations
CEO comments
The year 2019 was an important year for Optomed with several highlights,
including a very successful market expansion of our handheld fundus camera,
Aurora, opening of several complimentary sales channels for our products and
over-subscribed initial public offering (IPO) on Nasdaq Helsinki’s main list. We
now have the right products as well as the funds needed to grow and expand our
business to new markets and customer segments globally. Based on the Aurora
market expansion, our Distributor channel sales grew by 21.2 percent and our
private label distribution (OEM) by 13.8 percent and we started several direct
sales projects with our cameras and artificial intelligence (AI) based eye
screening solutions. Our software segment performed well, and revenue grew by
9.5 percent. This growth was mainly driven by success in the healthcare sector,
especially in the last quarter. Optomed group total revenue growth for 2019 was
3.6 percent.
During the year we expanded our distribution network to reach over 60 countries
in the EMEA and APAC regions. Our new Aurora camera was registered in several
new key markets, including Japan and Russia. In the second quarter we also
signed a new strategic OEM partnership with one of the leading global brands in
the ophthalmology equipment business. This new OEM camera called the “Signal”,
was launched to the market in September 2019, adding again one new important
sales channel for Optomed globally. Our direct sales team won new diabetic
retinopathy (DR) screening projects in Asia, Middle East and Africa, and part of
these projects already started to materialize as revenue during the year. The
eye screening projects, various pilots, clinical validation studies and other
commercialization activities led to strategically important early customers for
our Artificial Intelligence (AI) based solutions. AI is still in the very early
stages of commercialization in ophthalmology, but it is gaining momentum and
being incorporated into different healthcare systems in all main markets.
China is an important market for Optomed. We have our own subsidiary there with
15 employees in sales and marketing. In 2019, our business to the public
healthcare sector remained stable and predictable, but we faced some challenges
in our private healthcare business with one large private screening operator
postponing their camera orders from 2019 to the second half of 2020. We expect
the coronavirus outbreak to have a negative effect on our revenue, especially in
the first half of the year. Despite these challenges, we believe that the
fundaments for demand of our screening solutions in China are strong, and also
the private healthcare sector will recover in the near future. Our expected
highlights in China for 2020 are our Aurora camera CFDA-registration (China Food
and Drug Administration) and launch, as well as our large screening operator’s
recovery back to their normal order cycles.
We expect handheld cameras to continue gaining market share as one of the
fastest growing product categories within the global fundus camera market, and
large new screening programs for diabetic retinopathy continue to emerge
especially in Asia, Middle East, Africa and Latin America. Private screening
operators often choose to purchase handheld cameras instead of traditional
desktop machines because of mobility, ease of use and lower investment cost.
Also because of the limited amount of ophthalmologist resources available, AI
continues to gain clinical and commercial acceptance around the world. We
believe that we have the right products and a strong position to capitalize on
this opportunity in the coming years. In the first half of 2020 we will focus on
our growth strategy and take actions to expand our activities into new markets,
such as the United States. We are also investing heavily on the development of
our first, fully integrated AI camera, that can screen various eye diseases
easier, faster and more accurately than ever before. We expect to launch this
product in 2020.
Today, Optomed is a well-recognized medical technology company listed on Nasdaq
Helsinki and a world-leading manufacturer of handheld fundus cameras. In
combination with software and artificial intelligence, our cameras can make eye
screening more efficient and improve the availability and access to screening.
Our mission together with our partners and customers is to stop the growth of
avoidable blindness globally by bringing high quality and cost-effective eye
examinations to primary care.
I want to sincerely thank all our investors, both institutional and private, as
well as our employees, partners and customers for the trust and support of our
mission and growth strategy.
Seppo Kopsala, CEO
Outlook 2020
We continue to progress our expansion towards the US and grow our international
distributor network. Additionally, we are currently investing in the development
of our first fully integrated AI camera with expected commercial launch during
2020.
Optomed expects its revenue to grow during 2020 and that the growth will focus
on the second half of the year.
The COVID-19 Coronavirus outbreak may have a negative impact on the company’s
growth affecting both the business in China and the overall business due to the
company’s Chinese component suppliers. Further, in case the virus becomes
pandemic the company’s global sales could be negatively affected.
Group performance
October–December 2019
Group revenue decreased by 7.7 percent to EUR 4,329 (4,688) thousand in the
fourth quarter. Software segment performed well, and the revenue increased by
18.6 percent driven by a strong performance of services sales to healthcare
organizations. On the other hand, Devices segment’s revenue decreased by 24.4
percent. The decrease was mainly caused by a Chinese private screening operator
customer postponing orders from 2019 to 2020. The gross margin decreased from
75.3 percent to 63.4 percent. In 2018, the company received a governmental grant
of EUR 420 thousand, which increased the gross margin of the comparison period.
The fourth quarter 2018 gross margin adjusted for the total amount of the grants
would have been 66.3 percent. The remaining decrease of 2.9 percent was due to
segment and product mix.
EBITDA amounted to EUR 550 (968) thousand and adjusted EBITDA totaled EUR -211
(1,102) thousand. Adjusted EBITDA was positively affected by the
reclassifications of the IPO related expenses of EUR 760 (135) thousand from
operating expenses to equity in the fourth quarter 2019. The IPO related
expenses are classified as items affecting comparability. The EBITDA was also
negatively affected by the strengthening of the management, sales and marketing
functions as key investments in future growth. EBIT was EUR -33 (453) thousand
and adjusted EBIT was EUR -794 (588) thousand.
Net financial items amounted to EUR -67 (-102) thousand and consisted mainly of
interest payments to financial institutions and the translation effect of
Chinese RMB to EUR.
January–December 2019
Revenue increased by 3.6 percent to EUR 14,977 (14,463, pro forma) thousand for
the full year 2019. The revenue of the Devices segment decreased 2.0 percent
driven by the postponed Chinese orders. Software segment performed well and grew
9.5 percent, mainly due to the good performance of the healthcare sector.
EBITDA amounted to EUR -335 (1,188) thousand and adjusted EBITDA totaled EUR
-196 (1,661) thousand. Adjusted EBITDA was positively affected by the IPO
related expenses of EUR 139 (135). In 2018, the adjusted EBITDA was also
affected by Commit; Oy acquisition related expenses of EUR 191 thousand.
EBIT was EUR -2,596 (-664) and adjusted EBIT was EUR -2,457 (-338) thousand. The
IPO and acquisition related expenses are classified as items affecting
comparability.
Net profit was -2,875 (-1,327).
Net financial items amounted to EUR -356 (-555) thousand. Net loss per share was
EUR 0.32 (0.17).
Cash flow and financial position
Optomed’s cash position, balance sheet and equity ratio were significantly
strengthened by the IPO gross proceeds of EUR 20 million in December 2019. Total
IPO related fees and expenses amounted to EUR 4,208 in total, of which EUR 139
thousand was affecting the profitability and remaining EUR 4,069 thousand was
booked to equity.
In the fourth quarter, cash flow from operating activities amounted to EUR 2,000
(1,375) thousand, of which increase in trade and other payables explains the
positive variance versus 2018. In January–December 2019 cash flow from operating
activities amounted to EUR 161 (-76) thousand. Net cash used in investing
activities was EUR -1,434 (-8,765) for the full year 2019 and EUR -408 (-178)
for the fourth quarter. The full year increase was related to the acquisition of
Commit; Oy, and the main variance for the fourth quarter was sale of financial
asset in 2018.
Consolidated cash and cash equivalents at the end of the period amounted to EUR
18,866 (2,000) thousand. Interest-bearing net debt totalled EUR -8,938 (8,207)
thousand at the end of the period.
Net working capital was EUR 1,276 (1,640) thousand at the end of the year 2019.
Compared to the end of September 2019, the net working capital decreased by EUR
1,379 thousand, mainly due to increased trade and other payables.
Devices segment
Optomed has two synergistic business segments: Devices and Software.
The Devices segment develops, commercializes and manufactures easy-to-use, and
affordable handheld fundus cameras, that are suitable for any clinic for
screening of various eye diseases, such as diabetic retinopathy, glaucoma and
AMD (Age Related Macular degeneration).
EUR, thousand 10 10-12/2018 Change, % 1-12/2019 1-12/2018 Change, %
-12/20
19
Revenue 2,158 2,857 -24.4% 7,309 7,460 -2.0%
Gross profit * 1,114 2,087 -46.6% 4,200 5,053 -16.9%
Gross margin % 51.6% 73.0% 57.5% 67.7%
*
EBITDA -168 648 -126.9% -408 221 -284.6%
EBITDA margin -7.8% 22.7% -5.6% 3.0%
*, %
Operating -539 221 -343.9% -1,913 -1,323 -44.5%
result (EBIT)
Operating -25.0% 7.7% -26.2% -17.7%
margin (EBIT)
*, %
*) Alternative performance measures, see section Alternative Performance
Measures for definitions and calculations
EUR, 10 10-12/2018 Change, % 1-12/2019 1-12/2018 Change, %
thousand -12/20
19
Revenue by 2,158 2,856 -24.4% 7,309 7,460 -2.0 %
channel
- Distributor 560 561 -0.2% 1,662 1,370 21.3 %
s
- OEM 1,189 1,042 14.1% 3,373 2,964 13.8 %
- China 296 1,136 -73.9% 1,795 2,686 -33.2 %
- Other 113 117 -3.4% 479 440 8.9 %
October–December 2019
The Devices segment revenue decreased 24.4 percent in the fourth quarter.
Distributor sales were down 0.2 percent, OEM sales up 14.1 percent and China
sales down 73.9 percent. The key driver for the decrease was a Chinese key
customer postponing large orders to 2020. However, at the same time the OEM
business of the Devices segment performed well and executed initial shipments to
a new OEM customer, Topcon.
The gross margin decreased to 51.6 percent from 73.0 percent in the previous
year. In the fourth quarter 2018, the company received governmental grants of
EUR 420 thousand, which increased the gross margin of the comparison period. In
2018, the fourth quarter gross margin adjusted for the total amount of the
grants would have been 58.3 percent. The remaining decrease is related to
product and customer mix.
EBITDA was EUR -168 (648) thousand or -7.8 (22.7) percent of revenue. The key
driver for the decrease in EBITDA was the decreased revenue and higher operating
expenses related to new recruitments in sales and marketing functions.
January–December 2019
In January–December 2019, the Devices segment revenue decreased 2.0 percent and
was EUR 7,309 (7,460) thousand. The gross margin decreased from 67.7% to 57.5%
percent and EBITDA was EUR -408 (221) thousand or –5.6 (3.0) percent of revenue.
In 2018 the company received government grants of EUR 881 thousand, which
increased the gross margin of the comparison period.
The weakened financial performance was mainly due to a postponed order in China.
Software segment
Optomed has two synergistic business segments: Devices and Software.
The Software segment develops and commercializes screening software for diabetic
retinopathy and cancer screening for healthcare organizations. The segment also
distributes off-the-shelf products from selected partners to supplement its own
solutions and expertise and provides software consultation to support the
Devices segment screening solution projects.
Pro
forma
EUR, thousand 10 10 Change,% 1-12/20 1-12/2 Change, %
-12/20 -12/201 19 018
19 8
Revenue 2,171 1,831 18.6% 7,668 7,001 9.5%
Gross profit * 1,632 1,442 13.2% 5,744 5,344 7.5%
Gross margin % 75.2% 78.8% 74.9% 76.3%
*
EBITDA 477 320 49.1% 1,667 1,112 49.9%
EBITDA margin 22.0 17.5% 21.7% 15.9%
*, % %
Operating 264 233 13.3% 909 660 13.3%
result (EBIT)
Operating 12.2% 12.7% 11.9% 9.4%
margin (EBIT)
*, %
*) Alternative performance measures, see section Alternative Performance
Measures for definitions and calculations.
October–December 2019
Software segment had a strong fourth quarter and the revenue increased 18.6
percent and was EUR 2,171 (1,831) thousand. The increase was driven by a
successful delivery of new software solution projects and maintenance and
support services as well as growth in recurring license sales to various
healthcare organizations. EBITDA was EUR 477 (320) thousand or 22.0 (17.5)
percent of revenue, an increase of 49.1 percent.
January–December 2019
The Software segment’s revenue increased 9.5 percent and was EUR 7,668 (7,001)
thousand. The gross margin decreased from 76.3 percent to 74.9 percent. EBITDA
was EUR 1,667 (1,112) thousand or 21.7 (15.9) percent of revenue.
Software segment performance was driven by successful delivery of new software
solution projects and maintenance and support services as well as growth in
recurring license sales to various healthcare organizations.
Organic growth
The following table shows the organic growth of the group and the segments. The
adjusted elements are related to the acquisition of Commit; Oy executed in the
first quarter of 2018 and exchange rate variances between EUR and Chinese RMB.
Commit; Oy forms today the foundation of the Software segment.
Organic growth, percentage 10-12/2019 1-12/2019
Devices segment* -24.6% -2.4%
Software segment* 18.6% 6.9%
Group* -7.8% 1.5%
*) Alternative performance measures, see section Alternative Performance
Measures for definitions and calculations.
Group-wide expenses
Group-wide expenses relate to functions supporting the entire group such as
treasury, group accounting, legal, HR, IT and public listing expenses.
October–December 2019
Group-wide operating expenses amounted to EUR 617 thousand. Group-wide operating
expenses includes a reclassification of IPO expenses from operating expenses to
equity of EUR 760 (135) thousand. Group-wide expenses amounted to EUR 143
thousand excluding the IPO expenses. The IPO expenses are classified as items
affecting comparability.
January–December 2019
Group-wide operating expenses amounted to EUR 488 thousand. Group-wide expenses
include EUR 139 (135) thousand of IPO related expenses for the full year 2019.
For the financial year 2018, Group-wide expenses included Commit; Oy acquisition
related expenses of EUR 191 thousand. The acquisition and IPO related expenses
are classified as items affecting comparability.
IPO expenses
Total IPO related fees and expenses amounted to EUR 4,208 in total, of which EUR
139 thousand was affecting the profitability and the remaining EUR 4,069
thousand was booked to equity.
Personnel
Number of personnel at the end of the reporting period.
12/2019 12/2018
Devices 59 61
Software 36 36
Group common 13 8
Total 108 105
Corporate Governance
Optomed complies with Finnish laws and regulations, Optomed’s Articles of
Association, the rules of Nasdaq Helsinki and the Finnish Corporate Governance
Code 2020 issued by the Securities Market Association of Finland. The code is
publicly available at http://cgfinland.fi/en/. Optomed publishes its corporate
governance statement on the company website www.optomed.com
Annual General Meeting
The Annual General Meeting (“AGM”) of Optomed Plc was held on 10 May 2019. The
AGM adopted the financial statements and discharged the members of the Board of
Directors and the CEO from liability for the financial year 2018. The meeting
approved the Board of Directors’ proposal not to pay dividend for the year.
Petri Salonen, Matthew Hallam, Ingo Ramesohl, Anders Torstensson and Jun Wu were
re-elected and Seppo Mäkinen, Reijo Tauriainen and Jens Umehag were elected as
members of the Board. The Board of Directors elected Petri Salonen as the
Chairperson and the members of the Committees as follows:
Audit Committee: Reijo Tauriainen (chairperson) Petri Salonen, Matthew Hallam
and Jens Umehag.
Remuneration Committee: Petri Salonen (chairperson), Ingo Ramensohl and Anders
Torstensson.
Shares and shareholders
The company has one share series with all shares having the same rights. At the
end of the review period Optomed Plc's share capital consisted of 14,003,144
shares and the company held 811,000 shares in the treasury which corresponds
approximately 5.8 percent of the total amount of the shares and votes.
Additional information with respect to the shares, shareholding and trading can
be found on the company’s website www.optomed.com.
Risks and uncertainties
COVID-19 coronavirus
China has faced an outbreak of COVID-19 coronavirus in early 2020.
China is a major market for Optomed and the company also utilizes Chinese
suppliers in its supply chain.
The company may be adversely affected if the Chinese medical devices market
faces a prolonged downturn due to the outbreak. Further, the company may be
adversely affected in case Chinese component suppliers are not able to produce
and deliver components in sufficient quantities for the company to continue to
manufacture and deliver its devices. The company also recognizes the risk that
the virus may become pandemic which would have an adverse effect on the
company’s global sales.
High quality products
The quality and safety of the Company’s products are extremely important for
competitiveness.
The company may be adversely affected if it fails to continuously develop and
update its fundus cameras and software solutions or to identify or integrate new
products and product platforms into its offering.
Strategy and M&A
The company may be unsuccessful in fulfilling its strategy or the strategy
itself may be unsuccessful.
The successful implementation of the company’s strategy depends upon several
factors, some of which are completely or partially outside the company’s
control. The company has an appropriate risk management function in the context
of the size of the company's operations, however, it may not be able to identify
or monitor all relevant risks and determine efficient risk management procedures
and responsible persons that may again affect the strategy. The company is also
dependent on its ability to develop and manage varying routes-to-market for its
products, the efficiency of its sales channels and its customer and distributor
relationships. Further, the company has an opportunistic view on M&A which by
nature include inherent risks. Failure of strategy may force the company to
record write-downs on its goodwill.
Market and competition
The company operates in a market that is highly competitive.
Optomed operates in the fundus camera market that is developing fast and the
competition is sometimes fierce. The market acceptance of the company’s products
and solutions is important for its future growth. Optomed recognizes a
possibility of new market changing products entering the market. Further, in
certain key geographies Optomed’s client base is limited and, therefore, a loss
of a key customer in a key market may adversely affect the Company’s revenue
streams.
External economic and political risks and natural disasters
Optomed operates globally and is thus exposed to various external risks.
The company is exposed to natural disasters taking place in countries where it
operates. In addition to these, the company is also exposed to general and
country specific, economic, political and regulatory risks, which could entail
volatile sales in key markets.
Supply chain
Optomed's business is dependent on the effectiveness of purchasing materials,
manufacturing and timely distribution.
The company is dependent on contract manufacturers for functioning, efficient
and effective production and product assembly. Further, the company is dependent
on suppliers which may affect the company’s ability to supply its customers in a
timely manner.
Systems and information
Optomed’s operations are increasingly dependent on IT systems.
Disruption of the company's IT systems could inhibit the business operations in
a number of ways, including disruption to financial reporting, sales, production
and cash flows.
Litigation
Optomed operates globally and pursues double digit annual organic growth in
medium term.
Optomed may not always be able to reach the best contractual terms with
stakeholders. The company may be negatively affected by legal or administrative
proceedings directed at the company or third parties due to back-to-back
liability, or other disputes and claims including product liability, especially
in terms of medical devices, and intellectual property rights related items.
Trade secrets and patents
The technological capabilities are a competitive advantage that the company must
be able to protect.
The company may not be able to protect its trade secrets and know-how which
could lead to losing the competitive advantage the company has. At the same
time, the company may be forced to take actions against parties that violate
Optomed’s IPRs.
Talent & organisation
A skilled workforce and agile organisation are essential for the continued
success of the business.
The company may be adversely affected if it would lose its key personnel or
fails to attract the right talent.
Finance
The company needs external financing to operate and is not currently profitable.
The company is dependent on external financing and the company may have
difficulties accessing additional financing on competitive terms or at all which
may again contribute the company's liquidity risks. The company is also subject
to credit and counterparty risks through its trade receivables.
Forex
Optomed operates globally and is thus exposed to currency exchange risks.
The company is exposed to foreign exchange rate risks arising from fluctuations
in currency exchange rates, especially with regards to USD, EUR and RMB.
Currency rates, along with demand cycles, can result in significant swings in
the prices of the raw materials needed to produce the Company’s goods, sales
prices and OPEX.
Legal and regulatory
Compliance with laws and regulations is an essential part of Optomed’s business
operations.
Optomed and its’ suppliers and distributors operate globally and are subject to
various national and regional regulations in the areas of medical devices,
product safety, product claims, data protection, intellectual property rights,
health and safety, competition, employment, taxes and anti-money laundering and
anti-bribery & corruption (AML & ABC). Furthermore, many of the company's
devices are subject to various medical related assessment (including clinical
trials), clearance and approval processes that are required to introduce the
Company’s products on the markets.
Failure to comply with the regulations might lead to loss of sales permits in
different markets, product recalls, reputational issues, civil and criminal
actions leading to various direct and indirect damages to Optomed and its
employees that are not completely covered by Optomed's insurance coverage.
Especially, failures with respect to compliance with certain medical devices
related regulations and processes may hinder the company's devices market
access.
Other events
On 5 December 2019, trading of the company’s shares commenced on the prelist of
Nasdaq Helsinki Ltd and on the official list of Nasdaq Helsinki on 9 December
2019.
On 12 December 2019, the company announced that it has received a notification
from Universal-Investment-Gesellschaft mit beschränkter Haftung (“Universal
Investments”) according to which the total holdings in Optomed shares and votes
held by Universal Investments has increased to 7.49 per cent of all of the
registered shares in Optomed on 5 December 2019.
On 20 December 2019, the company announced the exercise of over-allotment option
in relation to the IPO of Optomed Plc and termination of the stabilisation
period.
The Board’s proposal for the distribution of profit
The parent company’s non-restricted equity on December 31, 2019 was EUR
21 736 790,31 and the net loss for the financial year was EUR 5,490,536.34. The
Board of Directors proposes to the Annual General Meeting that no dividend will
be paid and the non-restricted equity on the outstanding 14,003,144 shares shall
be retained and carried forward.
Events after the review period
On 28 January 2020, the company refinanced its bank loans and repaid an amount
of EUR 3,173 thousand.
On 3 February 2020, the company announced the proposal of the Nomination board.
The Nomination Board proposes to the Annual General Meeting 2020 that Seppo
Mäkinen, Petri Salonen, Reijo Tauriainen and Jun Wu are re-elected as Board
members and Anna Tenstam is elected as a new Board member.
Audit review
This Financial Statements Bulletin report has been audited by the company's
auditors.
Financial reporting in 2020
Week 12 at the latest Annual Report 2019
29 May 2020 Interim Report for 1 January – 31 March
2020
27 August 2020 Half-Year Financial Report for 1 January –
30 June 2020
25 November 2020 Interim Report for 1 January – 30 September
2020
For more information, contact
Lars Lindqvist, CFO
Tel.: +46 702 59 57 89
E-mail: lars.lindqvist@optomed.com
Seppo Kopsala, CEO
Tel.: +358 40 555 1050
E-mail: seppo.kopsala@optomed.com
About Optomed
Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld screening devices with
software and artificial intelligence with the aim to transform the diagnostic
process of blinding eye-diseases such as rapidly increasing diabetic
retinopathy. In its business Optomed focuses on eye-screening devices and
software solutions related R&D in Finland and sales through different channels
in over 60 countries. The company has an extensive portfolio of 55 international
patents protecting the technology. In 2019, Optomed’s revenue reached EUR 15
million and pro forma revenue amounted to EUR 14.5 million. At the end of 2019,
Optomed employed 108 professionals.
Alternative Performance Measures
Optomed uses certain alternative performance measures (APMs) with the purpose to
provide a better understanding of how the business develops. These APMs, as
defined, cannot be fully compared with other companies’ APMs.
Alternative Definition
Performance
Measures
Gross profit Revenue + Other operating income – Materials and services
expenses
Gross margin, % Gross profit / Revenue
EBITDA Operating result before depreciation, amortisation and
impairment losses
EBITDA margin, % EBITDA / Revenue
Operating result Profit/loss after depreciation, amortisation and
impairment losses
Operating margin, % Operating result / Revenue
Adjusted operating Operating result excluding items affecting comparability
result
Adjusted operating Adjusted operating result / Revenue
margin, %
Adjusted EBITDA EBITDA excluding items affecting comparability
Adjusted EBITDA Adjusted EBITDA / Revenue
margin %
Items affecting Material items outside ordinary course of business
comparability including restructuring costs, net gains or losses from
sale of business operations or other non-current assets,
strategic development projects, external advisory costs
related to capital reorganisation, impairment charges on
non-current assets incurred in connection with
restructurings, compensation for damages and transaction
costs related to business acquisitions.
Net Debt Interest-bearing liabilities (borrowings from financial
institutions, government loans and subordinated loans) –
cash and cash equivalents (excl. lease liabilities
according to IFRS 16)
Net Debt / Adjusted Net Debt / Adjusted EBITDA (for the last twelve months,
EBITDA (LTM), times LTM)
Earnings per share Net result / Number of outstanding shares (reflecting
changes in the number of shares following the resolution
of the EGM to split the shares of the Company with a
ratio of 1:20)
Equity ratio, % Total equity / Total assets
R&D expenses Employee benefit expenses for R&D personnel and other
operational expenses related to R&D activities
Organic growth, % Organic growth refers to revenue growth excluding (i)
growth attributable to acquisitions and divestments; and
(ii) growth attributable to fluctuations in exchange
rates. The various components in organic growth is
calculated as follows: Acquisitions and divestments:
Shows how acquisitions and divestments completed during
the relevant period have affected the reported revenues.
To estimate the impact of acquisitions on reported
revenue, the revenue from the contributions of the
acquired units for the current period is subtracted from
the total revenue for the same period. To estimate the
impact of divestments on reported revenue, the revenue
from the contributions from the divested units for the
current period is subtracted from the total revenue from
the previous respective comparison period. Currency
Fluctuations: Shows how the reported revenue has been
affected by the translation of revenue generated in other
currencies than the euro (which is the Group's accounting
currency) when there are exchange rate differences
between the current period and the corresponding
comparative period. Income in currencies other than euro
for the comparative period is recalculated using the
applicable exchange rate for the current period to
eliminate the effects of exchange rate fluctuations for
the relevant period.
Reconciliation of Alternative Performance Measures
In thousands of euro 10-12/2019 10-12/2018 2019 Pro forma 2018
Revenue 4,329 4,688 14,977 14,463
Other operating income 11 420 254 889
Material and services -1,595 -1,579 -5,287 -4,954
Gross profit 2,745 3,530 9,944 10,398
Operating profit/loss -33 453 -2,596 -664
(EBIT)
Items affecting
comparability
IPO related expenses -760 135 139 135
Acquisition related 0 0 0 191
expenses
Adjusted EBIT -794 588 -2,457 -338
Depreciation, 583 515 2,261 1,997
amortization and
impairment losses
Adjusted EBITDA -211 1,102 -196 1,661
Reconciliation of organic growth
Organic growth for the Group 10-12/2019 10-12/2018 2019 2018
Revenue 4,329 4,688 14,977 12,733
Acquisitions (elimination of 0 0 -2,029 0
revenues for comparability
Revenue excluding 4,329 4,688 12,948 12,733
acquisitions
Currency effects 0 6 0 26
Revenue excluding 4,329 4,694 12,948 12,759
acquisitions and currency
effects
Organic growth, percent -7.8% 1.5%
Organic growth for the 10-12/2019 10-12/2018 2019 2018
Devices segment
Revenue 2,158 2,856 7,309 7,460
Acquisitions (elimination of 0 0 0 0
revenues for comparability)
Revenue excluding 2,158 2,856 7,309 7,460
acquisitions
Currency effects 0 6 0 26
Revenue excluding 2,158 2,862 7,309 7,486
acquisitions and currency
effects
Organic growth, percent -24.6% -2.4%
Organic growth for the 10-12/2019 10-12/2018 2019 2018
Software segment
Revenue 2,171 1,831 7,668 5,273
Acquisitions (elimination of 0 0 -2,029 0
revenues for comparability)
Revenue excluding 2,171 1,831 5,639 5,273
acquisitions
Currency effects 0 6 0 0
Revenue excluding 2,171 1,837 5,639 5,273
acquisitions and currency
effects
Organic growth, percent 18.2% 6.9%
Consolidated income statement
The principles for describing events after the interim period are the same as
for events after the balance sheet date (IAS 10).
In thousands of euro Oct 1 - Jan 1 - Oct 1 - Jan 1 -
Dec 31, Dec 31 Dec 31, Dec 31, 2018
2019 2019 2018
Revenue 4,329 14,977 4,688 12,733
Other operating income 11 254 420 889
Materials and services -1,595 -5,287 -1,579 -4,568
Employee benefit -2,143 -7,299 -1,825 -5,137
expenses
Depreciation, -583 -2,261 -515 -1,810
amortisation and
impaiment losses
Other operating -52 -2,980 -738 -2,855
expenses
Operating result -33 -2,596 453 -748
Finance income -40 8 16 22
Finance expenses -107 -365 -118 -578
Net finance expenses -67 -356 -102 -555
Profit (loss) before -101 -2,952 351 -1,303
income taxes
Income tax expense 42 76 98 -24
Loss for the period -58 -2,875 449 -1,327
Loss for the period
attributable to
Owners of the parent -58 -2,875 449 -1,327
company
Loss per share
attributable to owners
of the parent company
Weighted average 8,935,654 8,935,654 7,775,473 7,775,473
number of shares
Basic loss per share -0,01 -0,32 0,06 -0,17
(euro)
Consolidated condensed comprehensive income statement
Loss for the period -58 -2,875 -476 -1,327
Other comprehensive income
Items that may be subsequently
reclassified to profit or loss
Foreign currency translation 10 14 5 13
difference
Other comprehensive income, 10 14 5 13
net of tax
Total comprehensive income -48 -2,861 -470 -1,314
for the period
Total comprehensive loss
attributable to
Owners of the parent company -48 -2,861 -470 -1,314
Consolidated balance sheet
In thousands of Dec 31, Dec 31,
euro 2019 2018
ASSETS
Non-current
assets
Goodwill 4,256 4,256
Development 5,218 5,172
costs
Customer 1,829 2,051
relationships
Technology 840 942
Other 540 376
intangible
assets
Total 12,662 12,796
intangible
assets
Tangible 406 739
assets
Right-of-use 1,075 1,084
assets
Financial 0 0
instruments
at fair value
Deferred tax 8 8
assets
Total non 14,151 14,627
-current assets
Current assets
Inventories 2,468 1,121
Trade and other 4,125 3,399
receivables
Cash and cash 18,866 2,000
equivalents
Total current 24,459 6,519
assets
Total assets 39,611 21,146
Share capital 80 19
Share premium 504 565
Reserve for 37,341 18,549
invested non
-restricted
equity
Translation 89 75
differences
Retained -12,500 -13,656
earnings
Profit (loss) -2,875
for the
financial year
Total equity 22,637 5,552
LIABILITIES
Non-current
liabilities
Borrowings from 5,104 -
financial
institutions
Government loans 2,998 2,993
Lease 699 727
liabilities
Preference share 0 694
liability
Deferred tax 616 693
liabilities
Total non 9,416 5,107
-current
liabilities
Current
liabilities
Borrowings from 1,766 7,010
financial
institutions
Government loans 60 204
Lease 414 393
liabilities
Trade and other 5,317 2,880
payables
Total current 7,557 10,487
liabilities
Total 16,973 15,594
liabilities
Total equity and 39,611 21,146
liabilities
Consolidated statement of changes in shareholders equity
Equity
attributable
to owners of
the parent
company
In thousands Note Share Share Reserve for invested Translation
Retained Total
of euro capital premium non-restricted equity differences
earnings
Balance at 19 565 18,549 75
-13,656 5,552
January 1,
2019
Comprehensive
income
Profit (loss) - - - -
-2,875 -2,875
for the
period
Translation - - - 14
14
differences
Total - - - 14
-2,875 -2,861
comprehensive
income for
the period
Transactions
with owners
of the
company
Share issue 19 61 -61 18,792 -
694 19,486
Share options 7 - - - -
461 461
Total 61 -61 18,792 -
1,155 19,947
transactions
with owners
of the
company
Balance at 80 504 37,341 89
-15,376 22,637
December 31,
2019
Equity
attributable
to owners of
the parent
company
In thousands Note Share Share Reserve Translation Retained
Total
of euro capital premium for differences earnings
invested
non
-restricted
equity
Balance at 19 565 13,049 62 -12,532
1,162
January 1,
2018
Comprehensive
income
Profit (loss) - - - -1,327
-1,327
for the
period
Translation - - - 13
13
differences
Total - - - 13 -1,327
-1,314
comprehensive
income for
the period
Transactions
with owners
of the
company
Share issue 19 - - 5,500 - -
5,500
Share options 7 - - - - 203
203
Total - - 5,500 - 203
5,703
transactions
with owners
of the
company
Balance at 19 565 18,549 75 -13,656
5,552
Dec 31, 2018
Consolidated cash flow statement
In thousands Oct Jan 1 - Oct 1 Jan 1 -
of euro 1 - Dec 31, - Dec 31,
Dec 2019 Dec 2018
31, 31,
2019 2018
Cash flows
from
operating
activities
Loss for the -58 -2,875 449 -1,327
financial
year
Adjustments:
Depreciation, 583 2,261 515 1,810
amortisation
and
impairment
losses
Finance 61 356 102 555
income and
finance
expenses
Other 166 466 -32 228
adjustments
Cash flows 752 207 1,033 1,267
before change
in net
working
capital
Change in net
working
capital:
Change in -468 -783 -217 -958
trade and
other
receivables
(increase (-)
/ decrease
(+))
Change in -135 -1,346 132 -50
inventories
(increase (-)
/ decrease
(+))
Change in 1,905 2,396 428 -126
trade and
other
payables
(increase (+)
/ decrease (
-))
Cash flows 2,054 475 1,377 133
before
finance items
Interest paid -55 -202 -66 -218
Other finance -17 -136 -5 -86
expenses paid
Interest 17 24 2 2
received
Income taxes 0 0 67 93
paid
Net cash from 2,000 161 1,375 -76
operating
activities
(A)
Cash flows
from
investing
activities
Acquisition -338 -1,175 -410 -1,295
of intangible
assets
Acquisition -70 -260 -148 -404
of tangible
assets
Proceeds from 0 0 0 8
sale of
intangible
assets
Proceeds from 0 0 0 133
sale of
tangible
assets
Acquisition 0 0 0 -7,604
of
subsidiary,
net of cash
acquired
Dividends 0 0 0 16
received
Proceeds from 0 0 380 380
sale of
financial
assets
Net cash used -408 -1,434 -178 -8,765
in investing
activities
(B)
Cash flows
from
financing
activities
Proceeds from 20,000 23,000 0 5,500
share
subscriptions
Share issue -4,208 -4,208 0 0
transaction
costs
Proceeds from 41 176 14 -5,192
loans and
borrowings
Repayment of -186 -460 -175 -537
loans and
borrowings
Repayment of -98 -385 -98 -342
lease
liabilities
Net cash 15,547 18,123 -259 9,814
from
financing
activities
(C)
Net cash 17,139 16,858 938 972
from (used
in)
operating,
investing
and
financing
activities
(A+B+C)
Net 17,139 16,858 938 972
increase
(decrease)
in cash and
cash
equivalents
Cash and 1,721 2,000 1,055 1,032
cash
equivalents
at
beginning
of period
Effect of 6 17 6 -5
movements
in exchange
rate on
cash held
Cash and 18,866 18,866 2,000 2,000
cash
equivalents
at end of
period
Selected notes
1. Corporate information and basis of
accounting
1.1 Corporate
information
Optomed is a Finnish medical technology group (hereafter ‘Optomed’ or ‘Group’)
that specialises in hand-held fundus cameras and solutions for screening of
blinding eye diseases, established in 2004.
The Group’s parent company, Optomed Plc. (hereafter the ‘Company’) is a Finnish
public limited liability company established under the laws of Finland, and its
business ID is 1936446-1. It is domiciled in Oulu, Finland and the Company’s
registered address is Yrttipellontie 1, 90230 Oulu, Finland.
1.2 Basis of
accounting
Optomed’s consolidated financial statements has been prepared in accordance with
International Financial Reporting Standards (IFRS) as adopted by the European
Union. The preparation of this interim report also takes into account the
amendments to IFRS standards that have become effective by September 30, 2019.
In the EU IFRS are standards and their interpretations adopted in accordance
with the procedure laid down in regulation (EC) No 1606/2002 of the European
Parliament and of the Council. Optomed has consistently applied these policies,
unless otherwise stated. The Group has not applied any standard, interpretation
or amendment thereto before its effective date.
This report have been prepared in accordance with IAS 34 Interim Financial
Reporting, and should be read in conjunction with Group`s last annual
consolidated financial statements as at and for the year ended 31 December 2019.
This Interim financial statements do not include all of the information required
for a complete set of IFRS financial statements: selected explanatory notes are
included to explain events and transactions that are significant to an
understanding of the changes in the Group`s financial position and performance
since the last annual financial statements.
This report has been were authorised for issue by the Company`s board of
directors.
Optomed’s financial statements are assuming that the Company will continue as a
going concern. The going concern basis presumes that the Group has adequate
resources to remain in operation, and that management intends to do so, for at
least one year from the date the financial statements are
signed.
Reportable segments
Q4/2019
In thousands of euro Devices Software Group Admin Group, IFRS
External revenue 2,158 2,171 4,329
Net operating expenses -1,044 -539 -1,584
Margin 1,114 1,632 2,744
Depreciation and amortisation -371 -213 -583
Other expenses -1,282 -1,155 242 -52
Operating result -539 264 242 -33
Finance items - - -67 -67
Loss before tax expense -539 264 175 -101
Q4/2018
In thousands of euro Devices Software Group Admin Group, IFRS
External revenue 2,857 1,831 4,688
Net operating expenses -770 -389 -1,159
Margin 2,087 1,442 3,530
Depreciation and amortisation -428 -86 -515
Other expenses -1,439 -1,122 -1,251
Operating result 221 233 454
Finance items 0 0 -102 -102
Loss before tax expense 221 233 -102 352
2019
In thousands of euro Devices Software Group Admin Group, IFRS
External revenue 7,309 7,668 14,977
Net operating expenses -3,109 -1,924 -5,033
Margin 4,200 5,744 - 9,944
Depreciation and amortisation -1,504 -757 -2,261
Other expenses -4,609 -4,077 -1,593 -10,279
Operating result -1,913 909 -1,593 -2,596
Finance items 0 0 -356 -356
Loss before tax expense -1,913 909 -1,949 -2,952
2018
In thousands of euro Devices Software Group Admin Group, IFRS
External revenue 7,460 5,273 12,733
Net operating expenses -2,132 -1,269 -3,401
Margin 5,328 4,004 9,332
Depreciation and amortisation -1,130 -166 -1,296
Other expenses -3,394 -2,036 -5,430
Operating result -1,559 358 -1,201
Finance items 0 0 -453 -453
Loss before tax expense -1,559 358 -453 -1,654
Revenue
In thousands of euro Q4/2019 Q4/2018 2019 2018
Finland 1,945 1,793 7,308 48,8 % 5,021 39,4 %
China 295 1,185 1,795 12,0 % 2,753 21,6 %
Other 2,087 1,712 5,874 39,2 % 4,960 39,0 %
Total 4,327 4,690 14,977 100,0 % 12,733 100,0 %
Tangible assets
In thousands of euro Machinery Machinery
and and
equipment equipment
2019 2018
Cost
Balance at January 1 1,729 1,185
Business combinations 274
Additions 262 270
Disposals - -
Effect of movements in - -
exchange rates
Balance at December 31 1,992 1,729
Accumulated depreciation
and impairment losses
Balance at January 1 -990 -555
Depreciation -595 -435
Impairment losses -
Effect of movements in -
exchange rates
Balance at December 31 -1,585 -990
Carrying amount at January 1 739 631
Carrying amount at December 31 406 739
Leases
Leased
tangible
assets
In thousands 31.12.2019 31.12.2018
of euro
Additions to 378 840
right-of-use
assets
Carrying 1,075 1,084
amount at
the end of
the
reporting
period
Leased
tangible
assets
comprise
business
premises and
are
presented
as a
separate
line item
Right-of-use
assets in
the
consolidated
balance
sheet.
Lease
liabilities
In thousands 31.12.2019 31.12.2018
of euro
Current 393
414
Non-current 699 727
Total 1,113 1,120
The weighted
average
Optomed's
incremental
borrowing
rate applied
for
discounting
purposes was
3.2 %.
The above
liabilities
are
presented on
the line
item Lease
liabilities
(non-current
/ current)
in the
consolidated
balance
sheet, based
on their
maturity.
Intangible assets and goodwill
At December Goodwill Develop Customer Technology Other
Total
31 2019 - relationships intangible
ment assets
costs
In thousands
of euro
Cost
Balance at 4,256 7,353 2,222 1,023 543
15,397
January 1
Business
-
combinations
Additions 894 - - 316
1,210
Balance at 4,256 8,246 2,222 1,023 859
16,606
December 31
-
Accumulated
-
amortisation
and
-
impairment
losses
Balance at - -2,181 -170 -82 -168
-2,601
January 1
Amortisation -848 -222 -102 -172
-1,344
Balance at -3,029 -392 -184 -340
-3,945
December 31
-
Carrying 4,256 5,172 2,051 942 376
12,796
amount at
January 1
Carrying 4,256 5,218 1,829 840 519
12,662
amount at
December 31
During twelve months ended 31 December 2019, no impairment losses were detected.
At December Goodwill Develop Customer Technology Other
Total
31, 2018 -ment relationships intangible
costs assets
In thousands
of euro
Cost
Balance at - 6,295 - - 261
6,557
January 1
Business 4,256 - 2,222 1,023 44
7,545
combinations
Additions - 1,058 - - 238
1,296
Balance at 4,256 7,353 2,222 1,023 543
15,397
December 31
Accumulated
amortisation
and
impairment
losses
Balance at - -1,480 - - -95
-1,575
January 1
Amortisation - -701 -170 -82 -73
-1,026
Balance at - -2,181 -170 -82 -168
-2,601
December 31
Carrying - 4,816 - - 166
4,982
amount at
January 1
Carrying 4,256 5,172 2,051 942 376
12,796
amount at
December 31
Capital and reserves
See financial covenants and covenant breach.
Financial liabilities
In thousands of euro 31.12.2019 31.12.2018
Non-current financial liabilities
Borrowings from financial institutions 5,104 -
Government loans 2,998 2,993
Subordinate loan - -
Lease liabilities 699 727
Preference share liability - 694
Total 8,800 4,414
Current financial liabilities
Borrowings from financial institutions 1,766 7,010
Government loans 60 204
Subordinate loan - -
Lease liabilities 414 393
Trade payables 1,667 732
Total 3,907 8,339
Total financial liabilities 12,707 12,753
Financial covenant and covenant breach
Optomed's borrowings from financial institutions contain a financial covenant
(equity ratio) and Optomed also has to meet certain key operative targets. The
related liabilities amounted to EUR 6,696 thousand (7,006 thousand at December
31, 2018). The borrowings will be repaid in accordance with the repayment
schedule.
Optomed has to comply with the financial covenant terms specified in the loan
agreement terms at the financial year-end. Equity ratio is calculated in FAS
figures using the agreed formula. The table below summarises the Group's
financial covenant term and compliance during 2018 and the reporting period.
Equity ratio
Covenant term Actual ratio Applicable level
At December 31, 2019 25 % 57,53 % Optomed Group
At December 31, 2018 35 % 34,65 % Optomed Group
The covenant was breached at December 31, 2018, and consequently the related
borrowings from financial institutions were classified as current as at
December 31, 2018.
Related party transactions
In thousands of euro Revenues Trade receivables Other expenses
Jan 1 - Dec 31 2019 2,200 1,172 -143
Jan 1 - Dec 31 2018 3,233 1,594 -74
Revenue and trade receivables and some of the other expenses relate to the major
shareholders of Optomed Ltd considered to be related parties to the parent
company.
Other expenses consist of consulting fees and travel expenses paid to the
Chairman of the Board of Directors.